GlassScriptPhysician profile
Kamal Sharma
NPI 1093914988
$37,172.10
in general payments reported to CMS, 2019-2025
77 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2021: $111 · 2022: $1,898 · 2023: $5,202 · 2024: $3,049 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $9,198 · Travel and Lodging: $1,355 · Education: $794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,588.75 |
| Food and Beverage | $9,197.53 |
| Travel and Lodging | $1,354.85 |
| Education | $793.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $7,909.23 | 2019-2025 | Eliquis, Opdivo |
| Stemline Therapeutics INC. | $7,681.12 | 2023-2025 | Orserdu |
| Astrazeneca Pharmaceuticals LP | $4,949.80 | 2019-2025 | Enhertu, Lynparza, Calquence |
| Celgene Corporation | $3,613.81 | 2019-2025 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $2,949.03 | 2019-2025 | Rybrevant, Erleada, Balversa |
| Pfizer INC. | $911.01 | 2022-2025 | |
| Incyte Corporation | $756.46 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Seagen INC. | $589.78 | 2022-2025 | Adcetris, Padcev, Tukysa |
| Merck Sharp & Dohme LLC | $445.41 | 2023-2025 | Keytruda, Lynparza, Reblozyl |
| Daiichi Sankyo INC. | $430.80 | 2022-2025 | Enhertu, Vanflyta, Datroway |
| Lilly USA, LLC | $425.89 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Astellas Pharma US INC | $422.87 | 2022-2025 | Xtandi, Padcev, Xospata |
| Genzyme Corporation | $400.35 | 2022-2025 | |
| Tempus Ai, INC | $378.53 | 2024-2025 | Xt Cdx |
| Novartis Pharmaceuticals Corporation | $377.28 | 2021-2025 | Piqray, Kisqali |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $326.08 | 2023-2025 | |
| Gilead Sciences, INC. | $323.82 | 2022-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $241.64 | 2023-2025 | Libtayo |
| Array Biopharma INC | $241.00 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Jazz Pharmaceuticals INC. | $223.92 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $213.40 | 2022-2025 | |
| Dendreon Pharmaceuticals LLC | $203.46 | 2024-2025 | Provenge |
| Abbvie INC. | $170.28 | 2023-2025 | Venclexta |
| Genentech USA, INC. | $160.44 | 2022-2025 | Tecentriq, Polivy, Lunsumio |
| Kite Pharma, INC. | $159.68 | 2022-2024 | Yescarta |
| Pharmaessentia USA Corporation | $147.01 | 2023-2025 | Besremi |
| Pharmacosmos Therapeutics INC. | $142.39 | 2022-2025 | Monoferric, Cosela |
| Puma Biotechnology, INC. | $127.56 | 2022-2025 | |
| Mirati Therapeutics, INC. | $127.08 | 2023-2024 | Krazati |
| Eisai INC. | $117.79 | 2023-2025 | |
| Coherus Oncology, INC. | $110.69 | 2024 | |
| Inari Medical, INC. | $97.30 | 2021 | |
| Alexion Pharmaceuticals, INC. | $91.12 | 2023-2024 | Ultomiris |
| Beigene USA, INC. | $90.15 | 2022-2025 | Brukinsa |
| Progenics Pharmaceuticals, INC. | $85.30 | 2023 | Pylarify |
| Takeda Pharmaceuticals U.S.A., INC. | $80.90 | 2023-2025 | Fruzaqla, Alunbrig, Vpriv |
| Aveo Pharmaceuticals, INC. | $79.91 | 2022-2023 | Fotivda |
| Telix Pharmaceuticals | $68.47 | 2023-2024 | Illuccix |
| Amgen INC. | $63.63 | 2022-2023 | Lumakras |
| Tersera Therapeutics LLC | $60.13 | 2023 | Zoladex |
| Taiho Oncology, INC. | $59.96 | 2025 | |
| Acrotech Biopharma INC. | $57.66 | 2022-2023 | Beleodaq |
| Beone Medicines USA, INC. | $57.65 | 2025 | Tevimbra, Brukinsa |
| Adc Therapeutics America, INC. | $56.69 | 2025 | |
| Agios Pharmaceuticals, INC. | $56.57 | 2023 | Pyrukynd |
| Rigel Pharmaceuticals, INC. | $52.89 | 2022-2023 | Rezlidhia, Tavalisse |
| Emd Serono, INC. | $51.46 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $51.16 | 2024 | Onpattro |
| Deciphera Pharmaceuticals INC. | $50.25 | 2024-2025 | Qinlock, Romvimza |
| Servier Pharmaceuticals LLC | $49.49 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $42.59 | 2023-2025 | Orgovyx |
| Myovant Sciences INC. | $42.12 | 2022 | |
| Shield Therapeutics INC | $39.56 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $39.32 | 2022 | |
| Morphosys, US INC. | $36.19 | 2022-2023 | Monjuvi |
| Legend Biotech USA INC. | $30.51 | 2025 | Carvykti |
| Amneal Pharmaceuticals LLC | $27.84 | 2025 | Alymsys |
| Pharmacyclics LLC, An Abbvie Company | $25.47 | 2023 | Imbruvica |
| Menarini Silicon Biosystems, INC. | $23.90 | 2024 | |
| Global Blood Therapeutics, INC. | $23.88 | 2022 | |
| Inogen, INC. | $23.81 | 2024 | |
| Fennec Pharmaceuticals, INC. | $23.45 | 2024 | Pedmark |
| Geron Corporation | $23.06 | 2025 | Rytelo |
| Boston Scientific Corporation | $22.65 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Recordati_rare_diseases_inc. | $22.60 | 2025 | Enjaymo |
| Blueprint Medicines Corporation | $22.30 | 2023 | Ayvakit |
| Genmab U.S., INC. | $21.88 | 2023 | Epkinly |
| Novocure INC. | $21.66 | 2025 | Optune Lua (Novottf-200t) |
| Organon LLC | $20.71 | 2023 | Ontruzant |
| Cti Biopharma Corp. | $18.62 | 2022 | |
| Ge Healthcare | $18.40 | 2022 | |
| Caris Mpi, INC. | $16.91 | 2025 | Mi Cancer Seek |
| Myriad Genetic Laboratories, INC. | $16.87 | 2023 | Myrisk |
| Verity Pharmaceuticals INC. | $14.95 | 2023 | Trelstar |
| Kyowa Kirin, INC. | $14.55 | 2023 | Poteligeo |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamal Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.